COMP <GO>
TMDX vs ABBV // EV/EBITDA & P/E VALUATION
TransMedics Group Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: TMDX 6
— ABBV 7
▲ EV/EBITDA & P/E VALUATION LEADER: TMDX
LAST: $67.12 (+0.33%) • MKT CAP: $2.33B
valuation
14.6x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TMDX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TMDX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.90% | 70.20% | -10.30 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.10% | 29.00% | -10.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 14.6x | 33.3x | -18.70 | TMDX | /valuation <GO> |
| Free Cash Flow Yield | 5.74% | 3.47% | +2.27 | TMDX | /fcf-yield <GO> |
| Operating Margin | 17.90% | 24.60% | -6.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 31.40% | 6.90% | +24.50 | TMDX | /net-margins <GO> |
| Revenue Growth (YoY) | 37.10% | 8.60% | +28.50 | TMDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.50 | 5.33 | -1.83 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | TMDX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 28.9 | 65.1 | -36.17 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.2x | 113.1x | -102.90 | TMDX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.33B | $513.86B | -$511.53B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TMDX REV | ABBV REV | TMDX GROSS % | ABBV GROSS % | TMDX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $605.5M | $61.16B | 59.9% | 70.2% | $133.6M | $17.82B |
| FY 2024 | $441.5M | $56.33B | 59.4% | 70.0% | -$80.9M | $17.83B |
| FY 2023 | $241.6M | $54.32B | — | — | -$13.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TMDX // BETA —
ABBV // BETA 1.15